https://www.rpharms.com/News instancehttps://www.rpharms.com/news/details//National-Patient-Safety-Alert---Shortage-of-dinoprostone-3mg-vaginal-tablets-and-1mg25ml-2mg25ml-vaginal-gelThe Department of Health and Social Care (DHSC) has published a National Patient Safety Alert regarding a shortage of dinoprostone 3mg vaginal tablets and 1mg/2.5ml, 2mg/2.5ml vaginal gel. Pfizer hasThu, 09 Apr 2026 12:16:14 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Bio-Products-Laboratory-Limited-Rabies-Human-normal-Immunoglobulin-500IU-solution-for-InjectionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 medicines recall for Human normal immunoglobulin 500IU solution for Injection. Bio Products Laboratory Limited isMon, 30 Mar 2026 13:46:37 GMThttps://www.rpharms.com/news/details//Freedom-of-Information-Scotland-Act-2002-and-Environmental-Information-Scotland-Regulations-2004The Scottish government has published an updated version of the Section 60 Code of Practice on the discharge of functions by Scottish public authorities under the Freedom of Information (Scotland) ActMon, 30 Mar 2026 08:20:56 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Sandoz-Limited-Apixaban-25mg-and-5mg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA)has published a Class 4 Medicines Defect Notification for Apixaban 2.5mg and 5mg Tablets. Sandoz Ltd. have informed the MHRA that the PatThu, 26 Mar 2026 14:51:13 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Quadrant-Pharmaceuticals-Limited-Vesomni-6-mg04-mg-modified-release-tabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Notification for Vesomni 6 mg/0.4 mg modified release tablets. Quadrant Pharmaceuticals LimitedThu, 26 Mar 2026 10:36:10 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Regent-Medical-Limited--Mlnlycke-Health-Care-Hibiwash-500mlThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 medicines recall for Regent Medical Limited / Mölnlycke Health Care, Hibiwash 500ml. Mölnlycke Health Care is recMon, 23 Mar 2026 16:52:43 GMThttps://www.rpharms.com/news/details//Update-Outbreak-of-invasive-meningococcal-disease-South-East-England-The UK Health Security Agency has issued an alert outlining priority steps in managing suspected cases, potential contacts of cases, and to reduce the risk of infection spreading. Note that this is a Wed, 18 Mar 2026 16:39:07 GMThttps://www.rpharms.com/news/details//Outbreak-of-meningococcal-disease-linked-to-University-of-Kent-and-the-area-of-Canterbury-EnglandThe Interim Chief Medical Advisor, (UKHSA) and Medical Director, (NHS England) have issued a letter regarding the outbreak of meningococcal disease linked to University of Kent and the area of CanterbWed, 18 Mar 2026 11:32:06 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Baxter-Healthcare-Corporation-Onkotrone-Injection-2-mgml-concentrate-for-solution-for-infusionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for Onkotrone Injection 2 mg/ml concentrate for solution for infusion. Baxter HealWed, 18 Mar 2026 09:04:21 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Rokshaw-Limited-Trading-as-Curaleaf-Laboratories-Curaleaf-Oil-FS-10mgml-THC-10mgml-CBD-30mlThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 Medicines Recall for specific batches of Curaleaf Oil [FS] 10mg/ml THC 10mg/ml CBD (30ml). Curaleaf LaboratoriesThu, 12 Mar 2026 14:54:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Bayer-Plc-Various-ProductsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 Medicines Recall for various products manufactured by Bayer Plc. Bayer Plc is recalling specific batches of GastThu, 12 Mar 2026 12:14:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Crescent-Pharma-Limited-Ramipril-5mg-capsules1The Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 medicines recall for ramipril 5mg capsules. Crescent Pharma Limited is recalling one batch of Ramipril 5 mg CapsuFri, 06 Mar 2026 16:17:06 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Rayner-Pharmaceuticals-Limited-Dropodex-01-wv-Eye-DropsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for Dropodex 0.1% w/v Eye Drops. Rayner Pharmaceuticals limited have informed the MWed, 25 Feb 2026 09:07:11 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Falsified-Mounjaro-KwikPen-15mg-pre-filled-pensThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update for Mounjaro KwikPen 15mg pre-filled pens. A falsified version of Mounjaro (tirzepatide) KwikPen 15mg soTue, 24 Feb 2026 15:03:05 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Sterling-Pharmaceuticals-Ltd-specials-manufacturer-MS-32515-KidNaps-Melatonin-1mg-in-1ml-Oral-SolutionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 medicines recall for KidNaps (Melatonin) 1mg in 1ml Oral Solution. Sterling Pharmaceuticals Ltd and Veriton PharmMon, 23 Feb 2026 12:05:50 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Norgine-Limited-MOVICOL-Ease-Citrus-Powder-for-oral-solution-137-gThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 3 medicines recall for a specific batch of Movicol Ease Citrus Powder for oral solution. Norgine Limited is recalliTue, 17 Feb 2026 10:50:00 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-IXCHIQ-Chikungunya-vaccine---updates-to-restrictions-of-use-following-safety-reviewThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update for IXCHIQ Chikungunya vaccine. Following the completion of a safety review and the recommendations of tThu, 12 Feb 2026 13:14:40 GMThttps://www.rpharms.com/news/details//Food-Standards-Agency-Danone-recalls-several-Aptamil-and-Cow--Gate-First-Infant-Milk-and-Follow-on-Milk-formula-products-because-of-the-possible-presence-of-cereulide-toxin-Danone is recalling several Aptamil and Cow & Gate First Infant Milk and Follow on Milk formula products because cereulide toxin may be present in some batches of the products. This recall is an eMon, 09 Feb 2026 10:40:37 GMThttps://www.rpharms.com/news/details//Semaglutide-Wegovy-Ozempic-and-Rybelsus-risk-of-Non-arteritic-Anterior-Ischemic-Optic-Neuropathy-NAIONThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update. Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden deterioraThu, 05 Feb 2026 14:20:11 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Aspar-Pharmaceuticals-Ltd-Ibuprofen-200mg-Tablets-Ibucalm-200mg-tabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 3 medicines recall for ibuprofen 200mg tablets and Ibucalm 200mg tablets. Aspar Pharmaceuticals Ltd is recalling spWed, 04 Feb 2026 15:25:36 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Syri-Limited-TA-SyriMed-Baclofen-10mg5ml-Oral-SolutionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 medicines recall for Baclofen 10mg/5ml oral solution. Syri Limited, T/A SyriMed is recalling specific batches of Tue, 03 Feb 2026 14:12:52 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Accord-Healthcare-Ltd-Carmustine-100-mg-Powder-and-Solvent-for-Concentrate-for-Solution-for-Infusion-1-vial-100mg-powder-1-vial-of-3-mL-solventThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 medicines recall for Carmustine 100 mg powder and solvent for concentrate for solution for infusion (1 vial 100mgMon, 02 Feb 2026 11:39:16 GMThttps://www.rpharms.com/news/details//Food-Alert-Danone-recalls-Aptamil-First-Infant-Formula-because-cereulide-toxin-has-been-found-in-this-batchThe Food standards agency (FSA) has published a food alert for Danone Aptamil First Infant Formula. Danone is recalling Aptamil First Infant Formula because cereulide toxin has been found in the produFri, 30 Jan 2026 09:51:14 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-GLP-1-receptor-agonists-and-dual-GLP-1GIP-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-casesThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update. The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucThu, 29 Jan 2026 15:46:32 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Class-1-Medicines-Recall-Notification-Recall-of-Quetiapine-Oral-Suspension-unlicensed-medicine-manufactured-by-Eaststone-Limited-due-to-a-potential-for-overdosingThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 1 medicines recall for Quetiapine Oral Suspension (unlicensed medicine). Eaststone Limited is initiating a recall oThu, 29 Jan 2026 14:36:06 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Viatris-Products-Ltd-Arixtra-solution-for-injection-pre-filled-syringesThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Notification for Arixtra solution for injection, pre-filled syringes. Viatris has informed the Wed, 28 Jan 2026 11:39:41 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Blumont-Pharma-Limited-Ocumont-Eye-Ointment-1--wwThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for Ocumont Eye Ointment 1% w/w. Blumont Pharma Limited has informed the MHRA abouTue, 27 Jan 2026 11:57:00 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Isotretinoin--changes-to-prescribing-guidance-and-additional-risk-minimisation-measuresThe Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. Healthcare profesFri, 23 Jan 2026 10:22:16 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Glenmark-Pharmaceuticals-Europe-Limited-Fingolimod-Glenmark-05-mg-Hard-CapsulesThe Medicines and Health products Regulatory Agency (MHRA) has published a class 3 recall for Fingolimod Glenmark 0.5 mg hard capsules. Glenmark Pharmaceuticals Europe Limited is recalling one batch aWed, 21 Jan 2026 11:54:18 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Mercury-Pharmaceuticals-Ltd-Paliperidone-Mercury-Pharma-prolonged-release-suspension-for-injection-in-pre-filled-syringesThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 medicines recall for paliperidone 50mg, 75mg, 100mg and 150mg prolonged-release suspension for injection in pre-fTue, 20 Jan 2026 14:28:16 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Reminder---Epimax-Ointment-and-Epimax-Paraffin-Free-Ointment---reports-of-ocular-surface-toxicity-and-ocular-chemical-injuryThe Medicines and Healthcare products Regulatory Agency (MHRA) is continuing to receive reports of ocular surface toxicity and ocular chemical injury where patients have been prescribed or advised to Fri, 16 Jan 2026 15:22:40 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-AlertNational Patient Safety Alert: Steriflex® No. 109 (1L) and No. 171 (2L): Potassium Chloride 0.15%, Sodium Chloride 0.45%, Glucose 2.5% Bags The Department of Health and Social Care (DHSC) has pubThu, 15 Jan 2026 10:41:34 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Improving-Information-Supplied-with-Gabapentinoids-PregabalinGabapentin-Benzodiazepines-and-Z-DrugsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update following a review of the warnings regarding addiction, dependence, withdrawal, and tolerance for gabaThu, 08 Jan 2026 13:19:59 GMThttps://www.rpharms.com/news/details//Food-Standards-Agency-Nestl-recalls-several-SMA-Infant-Formula-and-Follow-On-Formula-as-a-precaution-because-of-the-possible-presence-of-cereulide-toxinThe Food Standards Agency has published an alert for SMA Infant Formula and Follow-On Formula. Nestlé has taken the precautionary step of recalling several batches SMA Infant Formula and Follow-On ForThu, 08 Jan 2026 09:10:00 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Rybelsus-semaglutide-tablets-transition-to-new-formulation-and-risk-of-medication-errorThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug safety Update for Rybelsus (semaglutide) tablets. There is a risk of patient harm arising through medication error dThu, 18 Dec 2025 11:37:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Activase-Pharmaceuticals-Limited-Prednisolone-5mg-Soluble-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 medicines recall for prednisolone 5mg soluble tablets. Activase Pharmaceuticals Limited is recalling two batches Mon, 15 Dec 2025 14:16:00 GMThttps://www.rpharms.com/news/details//The-Human-Medicines-Authorisation-by-Pharmacists-and-Supervision-by-Pharmacy-Technicians-Order-2025--The Human Medicines (Authorisation by Pharmacists and Supervision by Pharmacy Technicians) Order 2025 was approved by Parliament and the Privy Council on the 11th December. These legislative changes Fri, 12 Dec 2025 10:50:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Hameln-Pharma-Ltd-Clarithromycin-500-mg-powder-for-concentrate-for-solution-for-infusionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 Medicines Recall forclarithromycin 500 mg powder for concentrate for solution for infusion. Hameln Pharma Ltd is Thu, 11 Dec 2025 12:00:06 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Flamingo-Pharma-UK-Ltd-Amitriptyline-Hydrochloride-10mg-25mg-50mg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Notification foramitriptyline hydrochloride 10mg, 25mg and 50mg tablets. Flamingo Pharma UK LtdWed, 10 Dec 2025 15:03:17 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Mesalazine-and-idiopathic-intracranial-hypertensionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update on mesalazine. Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients tFri, 05 Dec 2025 10:05:21 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Supply-of-licensed-and-unlicensed-epidural-infusion-bagThe Department of Health and Social Care (DHSC) has published a National Patient Safety Alert regarding supply issues affecting epidural infusion bags. There are supply issues affecting epidural bagsTue, 02 Dec 2025 12:39:55 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Special-Concept-Development-UK-Limited-Baclofen-10mg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for baclofen 10mg tablets. Special Concept Development UK Limited has informed the Thu, 27 Nov 2025 13:34:17 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Lexon-UK-Ltd-Moclobemide-150mg-tabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect notification for moclobemide 150mg tablets. Lexon UK Ltd has informed the MHRA that the Patient Tue, 25 Nov 2025 14:50:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Sun-Pharmaceutical-Industries-Limited-Fingolimod-SUN-05mg-hard-capsulesThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 medicines recall for Fingolimod SUN 0.5mg hard capsules. Sun Pharma UK Limited is conducting a precautionary recaThu, 20 Nov 2025 12:17:20 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Harm-from-incorrect-recording-of-a-penicillin-allergy-as-a-penicillamine-allergyNHS England has published a National Patient Safety Alert, in collaboration with the Royal Pharmaceutical Society, Royal College of Physicians and Royal College of General Practitioners on the risk ofThu, 20 Nov 2025 12:01:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Sun-Pharmaceutical-Industries-Limited-Atorvastatin-20mg-and-80mg-film-coated-tabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 3 medicine recall for atorvastatin 20mg and 80mg film-coated tablets. Sun Pharma UK Limited is recalling specific bTue, 11 Nov 2025 13:12:20 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Zambon-SpA-Emylif-50mg-orodispersible-filmThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 3 medicines recall for Emylif 50mg orodispersible film. Zambon SpA is recalling a specific batch as a precautionaryMon, 10 Nov 2025 13:41:25 GMThttps://www.rpharms.com/news/details//Influenza-Season-202526-Early-season-activity-and-implications-for-clinical-practiceUKHSA surveillance data indicates that influenza is circulating in the community earlier than usual this season with a drifted strain of Influenza A(H3N2) predominating. Clinicians should continue toWed, 05 Nov 2025 11:07:52 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Baxter-Healthcare-Limited-Compound-Sodium-Lactate-Solution-for-Infusion-BP-Hartmanns-Solution-for-infusion-in-Viaflo-1000mlThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 medicines recall for sodium lactate solution for infusion BP (Hartmann's Solution for infusion). Baxter HealtTue, 28 Oct 2025 11:33:29 GMThttps://www.rpharms.com/news/details//Drug-safety-Update-Isotretinoin-updates-to-prescribing-guidance-and-survey-of-servicesThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update on isotretinoin. The Commission on Human Medicines (CHM) has endorsed changes to isotretinoin prescribMon, 27 Oct 2025 14:37:41 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Accord-Healthcare-Ltd-Ipratropium-Bromide-500-microgram--2ml-Nebuliser-SolutionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 medicines recall for Ipratropium Bromide 500 microgram / 2ml Nebuliser Solution. Accord Healthcare Ltd is recalliThu, 23 Oct 2025 12:39:58 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Relonchem-Ltd-Various-ProductsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for specific batches of losartan potassium/Hydrochlorothiazide coated tablets and rThu, 23 Oct 2025 12:26:22 GMThttps://www.rpharms.com/news/details//MHRA-Drug-Safety-Update-Paracetamol-and-pregnancy---reminder-that-taking-paracetamol-during-pregnancy-remains-safeThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update for paracetamol in pregnancy. A recent US announcement suggested a link between paracetamol use in preWed, 24 Sep 2025 08:56:40 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-alert-Harm-from-delayed-administration-of-rasburicase-for-tumour-lysis-syndromeNHS England has published a National Patient Safety Alert on harm from delayed administration of rasburicase for tumour lysis syndrome. The alert requires action to prevent delays in the administratioTue, 09 Sep 2025 09:57:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Hikma-Farmacutica-Gemcitabine-2g526ml-concentrate-for-solution-for-infusionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for Gemcitabine 2g/52.6ml concentrate for solution for infusion. Hikma FarmacêuticaThu, 04 Sep 2025 13:27:20 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Ipca-Laboratories-UK-Limited-Various-ProductsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification. Ipca Laboratories UK Ltd has informed the MHRA that the Patient Information LeafleTue, 26 Aug 2025 12:52:18 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Fexofenadine-Hydrochloride-120mg-film-coated-tabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines notification for fexofenadine hydrochloride 120mg film-coated tablets. Chanelle Medical Unlimited CompaThu, 21 Aug 2025 11:50:41 GMThttps://www.rpharms.com/news/details//MHRA-Press-Release-Parents-and-caregivers-advised-to-stop-all-use-of-Nutrition-Ignition-Kids-Magnesium-Glycinate-Gummies-due-to-the-presence-of-undeclared-melatoninThe Medicines and Healthcare products Regulatory Agency (MHRA) is advising parents and caregivers to stop all use of Nutrition Ignition Kids Magnesium Glycinate Gummies, due to the presence of undeclaMon, 18 Aug 2025 13:19:07 GMThttps://www.rpharms.com/news/details//MHRA-Class-4-Medicines-Defect-Notification-Levetiracetam-Accord-100mgml-oral-solutionThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 medicines defect notification for Levetiracetam Accord 100mg/ml oral solution. Accord Healthcare Limited, UK has infThu, 14 Aug 2025 12:52:32 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Topiramate-Zydus-Pharmaceuticals-UK-20mgml-Oral-Solution-Zydus-Pharmaceuticals-UK-LtdThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution (pack size 150ml and Thu, 07 Aug 2025 09:27:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Fucidin-250-mg-Tablets-LEO-Laboratories-Ltd-trading-as-LEO-PharmaThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 medicines recall for Fucidin 250 mg Tablets. LEO Pharma is recalling a specific batch as a precautionary measure Mon, 04 Aug 2025 13:34:10 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Olmesartan-medoxomil-10mg-and-20mg-film-coated-tablets-Jubilant-Pharmaceuticals-NVThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for olmesartan medoxomil 10mg and 20mg film-coated tablets. Jubilant PharmaceuticalThu, 31 Jul 2025 11:11:32 GMThttps://www.rpharms.com/news/details//-National-Patient-Safety-Alert-Shortage-of-Antimicrobial-Agents-Used-in-Tuberculosis-TB-TreatmentThe Department of Health and Social Care has published a National Patient Safety Alert on the Shortage of Antimicrobial Agents Used in Tuberculosis (TB) Treatment. The following antimicrobial medicineWed, 30 Jul 2025 09:06:35 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-ChloraPrep-1mL-Clear-Sterile-SolutionApplicator-Becton-Dickinson-UK-LtdThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 medicines recall for ChloraPrep 1mL Clear Sterile Solution/Applicator. Becton Dickinson UK Ltd has informed the MMon, 28 Jul 2025 11:19:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Flutiform-250-micrograms--10-micrograms-per-actuation-pressurised-inhalation-suspension-The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for Flutiform 250 micrograms / 10 micrograms per actuation pressurised inhalation suspension. CD PhThu, 24 Jul 2025 13:15:50 GMThttps://www.rpharms.com/news/details//Device-safety-information-Trinity-Biotech-Premier-Hb9210-HbA1c-Analyser-Risk-of-Positive-Bias-and-Updates-to-Instructions-for-Use-including-use-as-a-diagnostic-aid-in-diabetes-mellitusThe Medicines and Healthcare products Regulatory Agency (MHRA) has received reports describing a positive bias in HbA1c results delivered by the Trinity Biotech Premier Hb9210 HbA1c analyser, which haTue, 22 Jul 2025 14:07:14 GMThttps://www.rpharms.com/news/details//Updated-National-Patient-Safety-Alert-Shortage-of-bumetanide-1mg-tabletsThe Department of Health and Social Care (DHSC) has provided an update that bumetanide 1mg tablets are now in limited supply until late July 2025. The supply disruption is caused by a combination of mFri, 11 Jul 2025 14:57:45 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Zaditen-025-mgml-eye-drops-solutionThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 Medicines Recall for Zaditen 0.25 mg/ml, eye drops, solution. Laboratoires Théa trading as Thea Pharmaceuticals LimiMon, 07 Jul 2025 13:16:17 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-of-bumetanide-1mg-tabletsBumetanide 1mg tablets are out of stock until mid August 2025. The supply disruption is caused by a combination of manufacturing issues and a resulting increase in demand to other suppliers. BumetanidFri, 04 Jul 2025 06:15:00 GMThttps://www.rpharms.com/news/details//UK-Government-restrictions-on-the-use-of-Puberty-Suppressing-Hormones-Puberty-Blockers-additional-information-for-prescribers-and-pharmacistsdispensing-doctors-ScotlandThe Chief Medical Officer (CMO) and the Chief Pharmaceutical Officer (CPhO) for Scotlandhas issued a letter with additional information on the restrictions on use of puberty supressing hormones.This iThu, 03 Jul 2025 15:51:47 GMThttps://www.rpharms.com/news/details//MHRA-Class-4-Medicines-Defect-Notification-Simvastatin-10mg-Tablet-Crescent-Pharma-LtdThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for simvastatin 10mg Tablet. Crescent Pharma Limited has informed the MHRA of an erThu, 03 Jul 2025 15:45:12 GMThttps://www.rpharms.com/news/details//Aurum-pre-filled-syringes-phased-introduction-of-new-10ml-CONNECT-syringe-barrel-Importance-of-selecting-compatible-needle-free-connectors-to-minimise-the-risk-of-syringe-blockageThe Medicines and Healthcare products Regulatory Agency (MHRA) has published device safety information for Aurum pre-filled syringes. Due to a phased introduction of the new 10ml CONNECT barrel desiTue, 01 Jul 2025 11:29:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Erythromycin-Stearate-BP-250mg-Tablets-Amdipharm-UK-LtdThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for erythromycin stearate BP 250mg tablets. Amdipharm UK Ltd has informed the MHRA Tue, 01 Jul 2025 11:26:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Tamoxifen-20mg-Film-Coated-Tablets-Wockhardt-UK-LtdThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 medicines recall for tamoxifen 20mg film-coated tablets. Wockhardt UK Limited is recalling a batch as a precautioMon, 30 Jun 2025 13:46:19 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Omeprazole-20-mg15-ml-Oral-Solution-Glenmark-Pharmaceuticals-Europe-LtdThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 medicines recall for Omeprazole 20 mg/15 ml Oral Solution. Glenmark Pharmaceuticals Europe Ltd is recalling a speMon, 30 Jun 2025 11:01:27 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Potential-contamination-of-non-sterile-alcohol-free-skin-cleansing-wipes-with-Burkholderia-spp-measures-to-reduce-patient-riskThe UK Health Security Agency (UKHSA) is investigating an outbreak of Burkholderia stabilis involving individuals across the UK, linked to wipes. Following testing, Burkholderia spp (full identificatiFri, 27 Jun 2025 09:24:55 GMThttps://www.rpharms.com/news/details//Updated-UKHSA-Immunisation-Training-standards-and-Quality-criteriaThe UK Health Security Agency (UKHSA) has published updated guidance on National Minimum Standards and Core Curriculum for Vaccination Training. This document sets the standards and lists the essentiaFri, 27 Jun 2025 09:02:54 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Depo-Medrone-80-mg-in-2-mL-suspension-for-injectionThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 Medicines Recall for Depo-Medrone 80 mg in 2 mL suspension for injection, Maxearn Limited. A batch of Depo-Medrone hWed, 25 Jun 2025 13:21:20 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Kimmtrak-200-microgramsmL-concentrate-for-solution-for-infusionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 medicines recall for Kimmtrak 200 micrograms/mL concentrate for solution for infusion. Immunocore Limited is recaWed, 25 Jun 2025 11:05:53 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Inhixa-12000IU-120mg08mL-solution-for-injectionThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 Medicines Recall for Inhixa 12,000IU (120mg)/0.8mL solution for injection. Maxearn Limited have informed the MHRA thThu, 12 Jun 2025 14:12:12 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Valproate-updated-safety-and-educational-materials-to-support-patient-discussion-on-reproductive-risksThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update for valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, EWed, 11 Jun 2025 08:15:38 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Dulcolax-Adult-5-mg-Gastro-resistant-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for Dulcolax Adult 5 mg Gastro-resistant Tablets. Opella Healthcare UK LTD has infoTue, 10 Jun 2025 11:11:14 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Paracetamol-500mg-Tablets-Chelonia-Healthcare-LimitedThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 medicines recall. Chelonia Healthcare Limited is recalling specific batches of paracetamol 500mg tablets (100 potMon, 09 Jun 2025 09:18:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Various-products-from-Zentiva-Pharma-UK-LimitedThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 Medicines Notification for various products from Zentiva Pharma UK Limited. Zentiva Pharma UK Limited has informed tMon, 02 Jun 2025 13:29:32 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Mercaptopurine-50mg-Tablets-Aspen-Pharma-Trading-LimitedThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 medicines recall. Aspen Pharma Trading Limited is recalling a specific batch of Mercaptopurine 50mg tablets as a Thu, 22 May 2025 10:44:42 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-BD-ChloraPrep-Clear---1mL-ApplicatorThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 Medicines Recall for BD ChloraPrep Clear - 1mL Applicator. Becton Dickinson UK Ltd has informed the MHRA that some uMon, 19 May 2025 13:24:46 GMThttps://www.rpharms.com/news/details//Influenza-season-202425-ending-the-prescribing-and-supply-of-antiviral-medicines-in-primary-careUK Health Security Agency (UKHSA) surveillance data indicates that circulation of influenza in the community has returned to baseline levels. In accordance with NICE guidance and Schedule 2 to the NaThu, 15 May 2025 13:45:54 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Chemidex-Pharma-Ltd-various-topical-steroid-products-The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 Medicines Notification for Chemidex Pharma Ltd topical steroid products.Chemidex Pharma Ltd has informed the MHRA thTue, 13 May 2025 10:49:12 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Chloramphenicol-Eye-OintmentThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 Medicines Defect Notification for Chloramphenicol 1% w/w Eye Ointment. Blumont Pharma Limited has informed the MHRA Thu, 08 May 2025 13:51:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Pregabalin-25mg-50mg-75mg-100mg-150mg-200mg-225mg-300mg-Capsules-Jubilant-Pharmaceuticals-NVThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for pregabalin 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules. JubilaTue, 29 Apr 2025 11:25:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Brilique-90mg-Tablets-ticagrelorThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification for Brilique 90mg Tablets. G Pharma Ltd has informed the MHRA that there is an erroThu, 24 Apr 2025 12:25:52 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Short-acting-beta-2-agonists-SABA-salbutamol-and-terbutaline-reminder-of-the-risks-from-overuse-in-asthma-and-to-be-aware-of-changes-in-the-SABA-prescribing-guidelinesThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update on short-acting beta 2 agonists (SABA) (salbutamol and terbutaline). Healthcare professionals are remiThu, 24 Apr 2025 11:21:46 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Lercanidipine-HCl-20mg-Tablets-Recordati-IndustriaThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 Medicines Recall for lercanidipine HCl 20mg Tablets. Recordati Pharmaceuticals Limited has informed the MHRA of an eThu, 17 Apr 2025 14:17:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Synalar-GEL-30g-and-Synalar-GEL-60gThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 Medicines Recall for Synalar GEL 30g and Synalar GEL 60g (fluocinolone acetonide 0.025%). It has been identified thaTue, 08 Apr 2025 12:34:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Renacet-475-mg-and-950-mg-Tablets-calcium-acetateThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 Medicines Defect Notification for Renacet 475 mg and 950 mg Tablets (calcium acetate). RenaCare NephroMed GmbH has iMon, 07 Apr 2025 14:25:56 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Urospir-50mg5ml-Oral-Solution-The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 medicines recall for Urospir 50mg/5ml Oral Solution. Rosemont Pharmaceuticals Limited is recalling a single batchWed, 02 Apr 2025 12:49:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Utrogestan-Vaginal-200-mg-Capsules-progesteroneThe Medicine and Healthcare products regulatory Agency (MHRA) has issued a class 2 medicines recall for Utrogestan Vaginal 200 mg Capsules. Uni Health Distribution Ltd has informed the MHRA of a typogTue, 01 Apr 2025 10:51:18 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Sirdupla-25-microgram250-microgram-per-metered-dose-pressurised-inhalation-suspensionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect notification for Sirdupla 25 microgram/250 microgram per metered dose pressurised inhalation, suMon, 31 Mar 2025 13:36:28 GMThttps://www.rpharms.com/news/details//UKHSA-Urgent-Public-Health-Message--Mpox-Clade-I-mpox-is-no-longer-classed-as-a-high-consequence-infectious-diseaseThe UK Health Security Agency has published an urgent public health message to all NHS trusts, GP practices and independent healthcare providers regarding the derogation of clade I mpox from a high coWed, 19 Mar 2025 14:11:22 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Discontinuation-of-Promixin-colistimethate-1-million-unit-powder-for-nebuliser-solution-unit-dose-vialsPromixin® (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) are being discontinued from early May 2025, with stocks anticipated to be exhausted by this date. Mon, 17 Mar 2025 14:16:28 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Prolonged-release-opioids-Removal-of-indication-for-relief-of-post-operative-painThe Medicines and Healthcare product Regulatory Agency (MHRA) has published a drug safety update on prolonged-release opioids. The indication for the treatment of post-operative pain has been removed Thu, 13 Mar 2025 09:43:10 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Notification-Azithromycin-250-mg-Capsules-The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 medicines defect notification for specific batches of azithromycin 250mg capsules. Jubilant Pharmaceuticals NV has iTue, 11 Mar 2025 15:37:29 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Boots-Paracetamol-500-mg-tablets-16sThe Medicine and Healthcare products Regulatory Agency (MHRA) has published a class 2 drug recall for Boots Paracetamol 500 mg tablets. Aspar Pharmaceuticals Limited have informed the MHRA of an errorTue, 04 Mar 2025 15:02:55 GMThttps://www.rpharms.com/news/details//Update-Class-2-Medicines-Recall-Sun-Pharmaceutical-Industries-Europe-BV-Pemetrexed-1000MG100ML-10mgml--800MG100ML-8mgml-Infusion-bagPlease note this alert has been updated to correct a typographical error in the strength of one product. The Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 recallTue, 04 Mar 2025 14:09:00 GMThttps://www.rpharms.com/news/details//MHRA-Class-3-Medicines-Recall-Azacitidine-100-mgvial-and-150-mgvial-Powder-for-Suspension-for-Injection-The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 3 recall for Azacitidine 100 mg/vial and 150 mg/vial Powder for Suspension for Injection. Accord Healthcare Limited isMon, 03 Mar 2025 12:07:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Glucophage-SR-500-mg-750mg-and-1000mg-Prolonged-release-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 medicines recall for Glucophage SR 500 mg, 750mg and 1000mg Prolonged-release tablets. All batches of the named pThu, 20 Feb 2025 14:39:17 GMThttps://www.rpharms.com/news/details//Food-Standards-Agency-TriOn-Pharma-recalls-Aactive-D3-2000iuml-supplements-because-of-excess-levels-of-Vitamin-D3TriOn Pharma is recalling two food supplement products. Aactive D3 Drops and Aactive D3 Solution because they contain higher levels of vitamin D3 than written on the label. This alert was published oTue, 18 Feb 2025 09:53:36 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Valproate-Belvo-Convulex-Depakote-Dyzantil-Epilim-Epilim-Chrono-or-Chronosphere-Episenta-Epival-and-Syonell-review-by-two-specialists-is-required-for-initiating-valproate-but-not-for-male-patients-already-taking-valproateThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update for Valproate products. The Commission on Human Medicines (CHM) has advised a review by two specialistThu, 13 Feb 2025 18:02:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Lansoprazole-Gastro-resistant-Hard-Capsules-15mgThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 Medicines Notification for Lansoprazole Gastro-resistant Hard Capsules 15mg. Teva UK Limited has reported a minor tyTue, 11 Feb 2025 12:04:33 GMThttps://www.rpharms.com/news/details//-Class-2-Medicines-Recall-Nitrofurantoin-CNX-Therapeutics-100-mg-Prolonged-Release-capsulesThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 medicines recall for specific batches of nitrofurantoin 100mg prolonged-release capsules. CNX therapeutics is recallWed, 05 Feb 2025 11:36:03 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Bristol-Laboratories-Limited-Amlodipine-Bristol-Lab-25-mg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for specified batches of Bristol Laboratories Limited, Amlodipine Bristol Lab 2.5 mg Tablets. The sThu, 30 Jan 2025 11:37:59 GMThttps://www.rpharms.com/news/details//GLP-1-and-dual-GIPGLP-1-receptor-agonistspotential-risk-of-pulmonary-aspiration-during-general-anaesthesia-or-deep-sedationThe Medicine and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update for GLP-1 and dual GIP/GLP-1 receptor agonists. Healthcare professionals should be aware of the potentiWed, 29 Jan 2025 14:06:18 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Tesco-Health-Dry-Cough-Relief-200ml-Asda-Strong-Dry-Tickly-Cough-200ml-Almus-Dry-Cough-Relief--Bells-Dual-Action-Dry-CoughThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for Tesco Health Dry Cough Relief 200ml, Asda Strong Dry Tickly Cough 200ml, Almus Dry Cough ReliefTue, 21 Jan 2025 15:05:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Irbesartan-150-mg-and-300-mg-film-coated-tabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines notification for Irbesartan 150 mg and 300 mg film-coated tablets. Jubilant Pharmaceuticals NV has infoMon, 13 Jan 2025 12:30:42 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Rabeprazole-sodium-10mg-and-20mg-gastro-resistant-tabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines notification for Rabeprazole sodium 10mg and 20mg gastro-resistant tablets. Bristol Laboratories LimiteThu, 09 Jan 2025 13:47:57 GMThttps://www.rpharms.com/news/details//Original-pack-dispensing-From 1 January 2025,NHS community pharmacists and their teams can dispense up to 10% more or less than the quantity prescribed of eligible medicines on NHS prescriptions if it means the medicine can bFri, 03 Jan 2025 09:43:11 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Argenx-BV-Vyvgart-1000-mg-solution-for-injectionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines notification for Argenx BV, Vyvgart 1000 mg solution for injection. Argenx BV has informed the MHRA thaThu, 19 Dec 2024 11:59:28 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-of-Pancreatic-enzyme-replacement-therapy-PERT-NatPSA2024013DHSC---Additional-actions-A National Patient Safety Alert has been issued on the shortage of pancreatic enzyme replacement therapy (PERT). This alert contains actions which are in addition to those outlined in the National PatWed, 18 Dec 2024 16:18:19 GMThttps://www.rpharms.com/news/details//Indefinite-ban-on-the-supply-of-puberty-blockers-to-children-and-young-people-under-18-years-of-ageSince 3 June 2024, temporary emergency restrictions have been in place preventing the private sale and supply of gonadotrophin releasing hormone (GnRH) analogues used to suppress puberty as part of trTue, 17 Dec 2024 12:23:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Wockhardt-UK-Limited-WockAIR-160-microgram45-microgram-inhalation-powder-budesonideformoterol-fumarate-dihydrateThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 drug recall for Wockhardt UK Limited, WockAIR 160 microgram/4.5 microgram, inhalation powder. Wockhardt UK Limited iMon, 09 Dec 2024 14:03:13 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Brillpharma-Limited-Oxybutynin-hydrochloride-Brillpharma-25-mg5-ml-Oral-SolutionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect information for Brillpharma Limited, Oxybutynin hydrochloride Brillpharma 2.5 mg/5 ml Oral SolutWed, 04 Dec 2024 11:59:36 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Kent-Pharma-UK-Phenoxymethylpenicillin-250mg5ml-Oral-Solution-Sugar-FreeThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 medicines recall for Kent Pharma UK, Phenoxymethylpenicillin 250mg/5ml Oral Solution Sugar Free. Kent Pharma UK iTue, 03 Dec 2024 16:05:59 GMThttps://www.rpharms.com/news/details//Influenza-Season-202425-Use-Of-Antiviral-Medicines-in-EnglandUK Health Security Agency (UKHSA) surveillance data indicates that influenza is circulating in the community. While some areas continue to see low levels of influenza activity, surveillance indicatorsTue, 03 Dec 2024 11:06:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Rosemont-Pharmaceuticals-Limited-Mycophenolate-Mofetil-1g5ml-Oral-SuspensionThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 medicine defect information for Rosemont Pharmaceuticals Limited, Mycophenolate Mofetil 1g/5ml Oral Suspension. RoseMon, 02 Dec 2024 15:55:30 GMThttps://www.rpharms.com/news/details//Legislative-changes-to-widen-access-to-naloxone-Following a consultation by the Department of Health and Social Care (DHSC), the Human Medicines Regulations (2012) (HMR) have been changed to widen access to naloxone. These changes come into force tMon, 02 Dec 2024 15:30:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Strides-Pharma-UK-Ltd-Liothyronine-Sodium-5--20-micrograms-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 medicines defect information. Strides Pharma UK Ltd has informed the MHRA of an error in the patient information leaThu, 28 Nov 2024 13:08:40 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Morningside-Healthcare-Limited-Tramadol-Hydrochloride-50-mg-capsules--Tramadol-Hydrochloride-Morningside-50-mg-Prolonged-Release-capsulesThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 medicines defect information for Morningside Healthcare Limited, Tramadol Hydrochloride 50 mg capsules & TramadoWed, 27 Nov 2024 15:18:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Syri-Limited-TA-SyriMed-Baclofen-10mg5ml-Oral-SolutionThe Medicines and Healthcare products regulatory Agency (MHRA) has issued a Class 3 medicine recall for Syri Limited, T/A SyriMed, Baclofen 10mg/5ml Oral Solution. Syri Limited, T/A SyriMed is recalliMon, 25 Nov 2024 15:13:14 GMThttps://www.rpharms.com/news/details//Folic-acid-supplementation-continued-advice-for-those-who-are-planning-a-pregnancy-or-newly-pregnantTheUK Chief Medical Officers, UK Chief Nursing Officers and UK Chief Midwifery Officers have published a letter with advice for healthcare professionals on folic acid supplementation for those who areMon, 25 Nov 2024 15:12:06 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Takeda-UK-Limited-Entyvio-vedolizumab108mg-solution-for-injection-in-pre-filled-syringeThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 medicines defect information for Takeda UK Limited, Entyvio (vedolizumab)108mg solution for injection in pre-filled Mon, 18 Nov 2024 16:43:13 GMThttps://www.rpharms.com/news/details//Company-led-medicines-recall-Leeds-Trading-Company-LTC-Ltd-TA-LTC-Healthcare-EXS-Delay-Spray-PlusLTC Healthcare has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that they have been selling a medicinal product containing lidocaine without authorisation from the MHRA. ThiThu, 14 Nov 2024 10:29:53 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Viatris-UK-Healthcare-Ltd-Omeprazole-40-mg-Powder-for-solution-for-infusionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect information for Omeprazole 40 mg Powder for solution for infusion. Generics (U.K.) Limited (MarkTue, 12 Nov 2024 11:38:52 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Ennogen-Healthcare-Limited-Zoledronic-Acid-Ennogen-4mg5ml-concentrate-for-solution-for-infusion1The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect information for Ennogen Healthcare Limited, Zoledronic Acid Ennogen 4mg/5ml concentrate for soluThu, 07 Nov 2024 15:03:00 GMThttps://www.rpharms.com/news/details//Puberty-blockers-temporary-ban-extended1We published apharmacy alerton 31 May 2024 on new restrictions on the sale and supply of gonadotrophin releasing hormone (GnRH) analogues when used to suppress puberty as part of treatment for gender Thu, 07 Nov 2024 14:14:45 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-GLP-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuseThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update for glucagon-like peptide-1 receptor agonists (GLP-1RAs). Healthcare professionals are reminded to infWed, 30 Oct 2024 10:08:14 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Tillomed-Laboratories-Limited-Labetalol-200mgThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 drug recall for a specific batch of Labetalol 200mg tablets. Tillomed Laboratories Limited is recalling one batch ofWed, 30 Oct 2024 09:30:00 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-of-Molybdenum-99Technetium99m-generatorsThe Department of Health and Social Care (DHSC) has issued a National Patient Safety Alert on the shortage of Molybdenum-99/Technetium99m generators. There are limited supplies of Molybdenum-99 used tMon, 28 Oct 2024 13:06:24 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Kent-Pharma-UK-Parasolve-Paracetamol-500mg-effervescent-tabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect information for Parasolve (Paracetamol) 500mg Effervescent Tablets. Kent Pharma UK has informed Mon, 28 Oct 2024 13:01:32 GMThttps://www.rpharms.com/news/details//UPDATE-Class-3-Medicines-Recall-Glenmark-Pharmaceuticals-Europe-Ltd-Cyanocobalamin-50-mcg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued an update to the Class 3 drug recall for cyanocobalamin 50 mcg tablets published on 3 October 2024. This recall notification Thu, 24 Oct 2024 07:35:00 GMThttps://www.rpharms.com/news/details//MHRA-Class-2-Medicines-Recall-Bristol-Laboratories-Ltd-Phenobarbital-Bristol-Labs-15mg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 drug recall for phenobarbital Bristol Labs 15mg Tablets. Bristol Laboratories Ltd. are recalling one batch of phenobWed, 23 Oct 2024 12:12:00 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Update-Discontinuation-Of-Kay-Cee-L-Potassium-Chloride-375mgMl-Potassium-Chloride-5mmol5ml-Syrup-Kay-Cee-L®(potassium chloride 5mmol/5ml) syrup will be discontinued from late November 2024 due to manufacturing and commercial issues. This alert supersedes the previous alert published on 26th JMon, 21 Oct 2024 15:35:44 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Kent-Pharma-UK-Paracetamol-500mg-Effervescent-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect information for Paracetamol 500mg Effervescent Tablets. Kent Pharma UK has informed the MHRA thaMon, 21 Oct 2024 11:16:07 GMThttps://www.rpharms.com/news/details//Safe-Spaces-ProgrammeThe Home Office has announced that it will be winding down the Ask for ANI emergency codeword scheme that was launched during the pandemic. Ask for ANI will conclude from 4th November 2024. The Safe Tue, 15 Oct 2024 14:39:37 GMThttps://www.rpharms.com/news/details//Guidance-on-reporting-safety-concerns-with-diabetes-management-equipment-to-the-Yellow-Card-schemeThe Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance on how to report suspected adverse incidents and safety concerns with diabetes management equipment to the Yellow Thu, 10 Oct 2024 14:52:31 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Sandoz-Ltd-Linezolid-600-mg-film-coated-tabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect information for linezolid 600mg film-coated tablets. Sandoz Ltd. has informed the MHRA that therThu, 10 Oct 2024 10:42:55 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Viatris-UK-Healthcare-Ltd-Trandolapril-2mg-and-4mg-capsulesThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 drug recall for Trandolapril 2mg and 4mg capsules. Generics (UK) Ltd T/A Mylan UK is recalling specific batches oMon, 07 Oct 2024 10:44:43 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Glenmark-Pharmaceuticals-Europe-Ltd-Cyanocobalamin-50-mcg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 drug recall for Cyanocobalamin 50 mcg tablets. Glenmark Pharmaceuticals Europe Ltd is recalling the affected batcThu, 03 Oct 2024 14:22:48 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Sandoz-Ltd-Rosuvastatin-20mg-40mg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Information for Rosuvastatin 20mg and 40mg Tablets. Sandoz Ltd. has informed the MHRA that thereTue, 01 Oct 2024 10:30:27 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Pfizer-Limited-Oxbryta-500mg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published aClass 2 medicines recall.Pfizer Limited is recalling all distributed batches of Oxbryta 500 mg Tablets. Pfizer Limited hasMon, 30 Sep 2024 11:56:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Sandoz-Ltd-Risperidone-1mg-2mg-3mg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Information for Risperidone 1mg, 2mg and 3mg and Tablets. Sandoz Ltd. has informed the MHRA thatThu, 26 Sep 2024 13:08:33 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Risk-of-oxytocin-overdose-during-labour-and-childbirthNHS England has issued a National Patient Safety Alert on the risk of oxytocin overdose during labour and childbirth. This instructs all relevant NHS funded maternity care providers to cease pre-prepaTue, 24 Sep 2024 15:04:45 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Orion-Pharma-UK-Ltd-Eldepryl-5mg-Tablets-selegilineThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 drug recall for Eldepryl 5mg Tablets (selegiline). Orion Pharma (UK) Ltd is recalling a specific batch of EldepryWed, 18 Sep 2024 08:19:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Theramex-HQ-UK-Ltd-Evorel-Sequi1The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 medicines recall for a batch of Evorel Sequipatches. Theramex has informed the MHRA that some cartons of Evorel SThu, 12 Sep 2024 10:51:19 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Valproate-use-in-men-as-a-precaution-men-and-their-partners-should-use-effective-contraceptionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update for valproate use in men. A retrospective observational study has indicated a possible association beThu, 05 Sep 2024 13:11:00 GMThttps://www.rpharms.com/news/details//Management-of-eye-conditions-in-primary-care-for-contact-lens-wearing-patients-Following discussion with the College of Optometrists we would like to highlight our guidance on Chloramphenicol (P Medicines). This includes a section on advice for contact lens wearers. People presWed, 28 Aug 2024 13:31:30 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Chemidex-Pharma-Ltd-Ponstan-250mg-Capsules--500mg-Tablets-mefenamic-acidThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Information for specific batches of Ponstan 250mg Capsules and 500mg Tablets. Chemidex Pharma LtTue, 27 Aug 2024 12:50:45 GMThttps://www.rpharms.com/news/details//Puberty-blockers-temporary-ban-extendedWe published apharmacy alerton 31 May 2024 on new restrictions on the prescription and supply of puberty blockers. Since 3 June 2024, in Great Britain, temporary emergency restrictions have been in plFri, 23 Aug 2024 14:36:25 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Glenmark-Pharmaceuticals-Europe-Ltd-Fingolimod-05-mg-Hard-CapsulesThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 3 recall for Fingolimod 0.5 mg Hard Capsules. Glenmark Pharmaceuticals Europe Ltd is recalling specific batches after Mon, 19 Aug 2024 09:45:00 GMThttps://www.rpharms.com/news/details//Clade-I-mpox-virus-infection-UpdateFollowing the notification of the urgent public health message regarding Clade I mpox virus (MPXV) infection, the UK Health Security Agency (UKHSA) hasmade updates to the Management of Cases section. Fri, 16 Aug 2024 12:39:00 GMThttps://www.rpharms.com/news/details//Clade-I-mpox-virus-infectionThe UK Health Security Agency has issued an urgent public health message to all NHS service providers regarding Clade I mpox virus (MPXV) infection. The guidance includes information on: Actions toFri, 16 Aug 2024 07:18:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Strides-Pharma-UK-Limited-Loperamide-Hydrochloride-Capsules-2mgThe Medicines and Healthcare products Regulatory Agency (MHRA) has published aClass 2 medicines recall for a specified batch of Strides Pharma UK Limited, Loperamide Hydrochloride Capsules 2mg. StrideThu, 15 Aug 2024 08:22:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Dawa-Limited-Trazodone-Hydrochloride-50mg--100mg-Capsules-and-Trazodone-Hydrochloride-50mg5ml-Oral-SolutionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Information for specific Trazodone products. Dawa Limited has informed the MHRA of an error withWed, 14 Aug 2024 12:20:48 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Star-Pharmaceuticals-Limited-Diflucan-Oral-Suspension-40mgmlThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines notification for Diflucan Oral Suspension 40mg/ml. Star Pharmaceuticals Limited has informed the MHRA tMon, 12 Aug 2024 11:21:34 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Accord-UK-Ltd-Trandolapril-05mg-2mg-4mg-CapsulesAccord-UK Ltd is recalling various batches of Trandolapril 0.5mg, 2mg and 4mg capsules after retesting showed out of specification results. The batches are being recalled as a precautionary measure afThu, 08 Aug 2024 10:54:01 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Sandoz-Limited-Omeprazole-productsThe Medicines and Healthcare regulatory Agency (MHRA) has issued a Class 4 Medicines Defect Information for a number of Omeprazole products. Sandoz Ltd. has informed the MHRA that there is missing safWed, 07 Aug 2024 12:41:50 GMThttps://www.rpharms.com/news/details//Puberty-Suppressing-Hormones-Judicial-Review-and-RPS-position-statementWe published a pharmacy alert on 31 May 2024 on new restrictions on the prescription and supply of puberty blockers. This legislative change introduced a temporary ban (ending on 3 September) on the pWed, 31 Jul 2024 13:20:13 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Glenmark-Pharmaceuticals-Europe-Ltd-Atomoxetine-10mg-18mg-25mg-40mg-60mg-80mg--100mg-Hard-CapsulesGlenmark Pharmaceuticals Europe Ltd is recalling various batches of atomoxetine 10mg, 18mg, 25mg, 40mg, 60mg, 80mg and 100mg Hard Capsules after retesting showed out of specification results. The batcTue, 30 Jul 2024 09:47:15 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert--Shortage-of-Kay-Cee-L-potassium-chloride-375mg5ml-potassium-chloride-5mmol5ml-syrupKay-Cee-L(potassium chloride 5mmol/5ml) syrup will be out of stock from late September 2024. The resupply date is to be confirmed. The supply disruption is caused by an amendment to the manufacturingFri, 26 Jul 2024 10:40:25 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Aspen-Pharma-Trading-Limited-Co-trimoxazole-80mg400mg-per-5ml-adult-suspensionAspen Pharma Trading Limited has informed The Medicines and Healthcare Regulatory Agency (MHRA)that an error has been found in the Patient Information Leaflet (PIL) for Co-trimoxazole 80mg/400mg per 5Thu, 25 Jul 2024 14:00:44 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Fresenius-Kabi-Limited-Hartmanns-Solution-for-Injection-BP-as-Steriflex-No-11-or-freeflexThe Medicines and Healthcare Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Information for Fresenius Kabi Limited, Hartmann's Solution for Injection BP as Steriflex No. 11 or fWed, 24 Jul 2024 13:21:38 GMThttps://www.rpharms.com/news/details//Epimax-Ointment-and-Epimax-Paraffin-Free-Ointment-reports-of-ocular-surface-toxicity-and-ocular-chemical-injuryThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update due to reports of ocular surface toxicity and ocular chemical injury for Epimax Ointment and Epimax ParafTue, 23 Jul 2024 15:46:55 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Glaxo-Wellcome-UK-Limited-trading-as-GlaxoSmithKline-UK-Flolan-15-mg-Powder-and-Solvent-for-Solution-for-InfusionThe Medicines and Healthcare products regulatory Agency (MHRA) has published as Class 2 medicines recall for Flolan 1.5 mg Powder and Solvent for Solution for Infusion. Glaxo Wellcome UK Ltd (GSK) hasTue, 23 Jul 2024 08:30:51 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Sun-Pharma-UK-Limited-Pemetrexed-1000MG100ML-10mgml--1100MG100ML-11mgml-Infusion-BagSun Pharmaceutical Industries Europe B.V. is recalling specified batches of Pemetrexed 1000mg/100ml (10mg/ml) and 1100mg/100ml (11mg/ml) infusion bag as a precautionary measure due to visible particulTue, 16 Jul 2024 10:14:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Sun-Pharma-UK-Limited-GemcitabineSun Pharma UK Ltd is recalling specified batches as a precautionary measure due to a small number of leaks found intermittently in the infusion bags. Advice for healthcare professionals is to use preMon, 15 Jul 2024 10:19:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Chelonia-Healthcare-Limited-Propantheline-Tablets-15mg-Chelonia Healthcare Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that an error relating to the product description was identified in the Patient Information LeafTue, 09 Jul 2024 11:01:15 GMThttps://www.rpharms.com/news/details//MHRA-Class-2-Medicines-Recall-Kent-Pharma-UK-Itraconazole-10mgml-Oral-SolutionKent Pharma UK is recalling specified batches of Itraconazole 10mg/ml Oral Solution as a precautionary measure due to out of specification in the appearance of the solution, particularly the presence Thu, 04 Jul 2024 12:18:50 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Accord-Healthcare-Ltd-Atomoxetine-10mg-18mg-25mg-40mg-60mg-80mg-100mg-Hard-CapsulesAccord Healthcare Ltd is recalling various batches of atomoxetine 10mg, 18mg, 25mg, 40mg, 60mg, 80mg and 100mg Hard Capsules after retesting showed out of specification results. The batches are being Tue, 02 Jul 2024 12:30:18 GMThttps://www.rpharms.com/news/details//Introduction-of-new-NHS-vaccine-programmes-against-respiratory-syncytial-virus-RSV-Scotland-The Chief Medical Officer has issued a letter that information on a new vaccination programme in Scotland which aims to protect vulnerable groups against Respiratory Syncytial Virus (RSV) and its compWed, 26 Jun 2024 09:41:23 GMThttps://www.rpharms.com/news/details//Introduction-of-new-NHS-vaccine-programmes-against-respiratory-syncytial-virus-RSV-EnglandThe UK Health Security Agency (UKHSA) and NHS England have published a letter which sets out the details of respiratory syncytial virus (RSV)vaccination programmes. Following guidance from the Joint CWed, 26 Jun 2024 09:38:36 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-PHARMATHEN-SA-Grepid-75-mg-film-coated-tablets-Kent-Pharma-LiveryThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 Medicines Defect Information for Grepid 75mg film coated tablets. PHARMATHEN S.A. has informed the MHRA that the outMon, 24 Jun 2024 13:03:46 GMThttps://www.rpharms.com/news/details//Topiramate-Topamax-introduction-of-new-safety-measures-including-a-Pregnancy-Prevention-ProgrammeThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update on the introduction of new safety measures, including a Pregnancy Prevention Programme for topiramate. ToThu, 20 Jun 2024 10:41:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Teva-UK-Limited-GoResp-DigihalerTeva UK Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that it plans to withdraw from further sale all batches of GoResp Digihaler (budesonide and formoterol fumarTue, 18 Jun 2024 14:28:40 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Viatris-UK-Healthcare-Ltd-Oxcarbazepine-Mylan-150-mg-300mg-600mg-Film-Coated-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 Medicines Defect Information for Oxcarbazepine Mylan 150 mg, 300mg, 600mg Film-Coated Tablets. Viatris UK HealthcareMon, 17 Jun 2024 16:11:59 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Dawa-Limited-Paracetamol-500mg-1000mg-Film-Coated-TabletDawa Limited has informed the MHRA that certain batches of paracetamol have been packed with an outdated Patient Information Leaflet (PIL). The PIL does not contain the most up to date information on Wed, 12 Jun 2024 10:22:27 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Desitin-Pharma-UK-Ltd-Lamotrigine-Desitin-10mgml-Oral-SuspensionDesitin Pharma UK Ltd is recalling all batches of Lamotrigine Desitin 10mg/ml Oral Suspension as a precautionary measure due to an out of specification observation in the appearance of samples during Fri, 07 Jun 2024 08:39:47 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Neuraxpharm-UK-Ltd-Atomoxetine-10mg-18mg-25mg-40mg-CapsulesNeuraxpharm UK Ltd is recalling specific batches ofAtomoxetine 10mg, 18mg, 25mg, 40mg Capsules after retesting showed out of specification results. Specified batches are being recalled as a precautionWed, 05 Jun 2024 13:10:00 GMThttps://www.rpharms.com/news/details//New-UK-Government-restrictions-on-the-supply-of-Puberty-Suppressing-Hormones-Puberty-Blockers-Information-of-prescribers-and-pharmacistsdispensing-doctorsWe published a pharmacy alert on 31 May 2024 on new restrictions on the prescription and supply of puberty blockers. The Chief Pharmaceutical Officer and Chief Medical Officer for Wales have issued a Mon, 03 Jun 2024 11:46:25 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Manx-Healthcare-Ltd-Betamethasone-Valerate-01-OintmentThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect information for Betamethasone Valerate 0.1% Ointment. Manx Healthcare Ltd. has informed MHRA thaMon, 03 Jun 2024 09:40:00 GMThttps://www.rpharms.com/news/details//New-restrictions-on-the-prescription-and-supply-of-puberty-blockersThere will be upcoming legislative changes that introduce new restrictions on the prescribing and supply of puberty supressing hormones known as ‘puberty blockers’, to children and young pFri, 31 May 2024 07:58:00 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Topical-steroids-introduction-of-new-labelling-and-a-reminder-of-the-possibility-of-severe-side-effects-including-Topical-Steroid-Withdrawal-ReactionsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update for topical steroids. Topical steroid products are safe and highly effective treatments for the manageWed, 29 May 2024 15:31:24 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-of-Pancreatic-enzyme-replacement-therapy-PERTThere are limited supplies of pancreatic enzyme replacement therapies (PERT). • Creon® 10,000 and 25,000 capsules are in limited supply until 2026. • Nutrizym® 22 capsules are out Fri, 24 May 2024 15:39:40 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Fresenius-Kabi-Limited-Sodium-Chloride-09-Intravenous-Infusion-BP-Freeflex-and-Freeflex-PlusFresenius Kabi Limited have informed the MHRA of a packaging error with specific batches of Sodium Chloride Intravenous Infusion 0.9% Freeflex and Freeflex PLUS. Further information, advice and detaiWed, 22 May 2024 13:22:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Defect-Information-Doncaster-Pharma-Limited-Keppra-500mg-film-coated-tabletsThe MHRA has re-issued this notification as Class 3 recall based on further assessment. Please note the new actions for healthcare professionals listed within the notification. Doncaster Pharma LimiteWed, 22 May 2024 10:31:58 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Cygnus-Pharma-Ltd-Trazodone-Hydrochloride-50mg5ml-Oral-SolutionCygnus Pharma Ltd. has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the European Article Number (EAN) barcode printed on various packs of Trazodone Hydrochloride 50mg/5Mon, 20 May 2024 13:57:47 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Doncaster-Pharma-Limited-Keppra-500mg-film-coated-tabletsDoncaster Pharma Limited have identified an error relating to the Braille printed on the cartons on various parallel imported packs which have been repackaged by BModesto B.V. Approximately 70% of thWed, 15 May 2024 13:50:25 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-Of-Erelzi-Etanercept-50mg-Solution-For-Injection-In-Pre-Filled-PenErelzi (etanercept) 50mg solution for injection in pre-filled pen will be out of stock from early May until mid-July 2024. Homecare providers (Alcura, Healthnet and Sciensus) have sufficient stock to Fri, 03 May 2024 11:11:25 GMThttps://www.rpharms.com/news/details//NHS-England-Influenza-Season-202324-Ending-The-Prescribing-And-Supply-Of-Antiviral-Medicines-In-Primary-CareUK Health Security Agency (UKHSA) surveillance data indicates that circulation of influenza in the community has returned to baseline levels. In accordance with NICE guidance and Schedule 2 to the NaFri, 03 May 2024 10:43:07 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Finasteride-reminder-of-the-risk-psychiatric-side-effects-and-of-sexual-side-effects-which-may-persist-after-discontinuation-of-treatmentA patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunctiTue, 30 Apr 2024 10:22:19 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Montelukast-Reminder-of-the-risk-of-neuropsychiatric-reactionsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update to remind healthcare professionals to be alert to the of the risk of neuropsychiatric reactions in peoTue, 30 Apr 2024 10:20:37 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Neon-Healthcare-Ltd-Suprefact-1-mgml-solution-for-injection-Cheplapharm--Canadian-LiveryNeon Healthcare Ltd is recalling a specific batch of Suprefact 1 mg/ml solution for injection as a precautionary measure. This is because the batch is being distributed in packaging intended for the CTue, 23 Apr 2024 15:09:34 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Accord-UK-Ltd-Co-Codamol-8500mg-Effervescent-Tablets-Key-Pharmaceuticals-LiveryAccord-UK Ltd is recalling a specific batch of Co-Codamol 8/500mg Effervescent Tablets (Key Pharmaceuticals Livery) as a precautionary measure due to the internal tablet blister strips being printed wWed, 10 Apr 2024 10:32:58 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-UKHSA-Update-to-advice-provided-for-carbomer-containing-lubricating-eye-productsIn December 2023 the UK Health Security Agency (UKHSA) investigated an outbreak of Burkholderia cenocepacia involving individuals across the UK. This was an emerging issue and, followed testing, B. ceWed, 03 Apr 2024 09:29:57 GMThttps://www.rpharms.com/news/details//MHRA-Device-Safety-Information-Counterfeits-and-unbranded-copies-of-LifeVac-anti-choking-devices-may-fail-to-work-correctly-or-worsen-choking-incidents-if-usedThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued Device Safety information for counterfeits and unbranded copies of LifeVac anti-choking devices. Anti-choking devices are intMon, 25 Mar 2024 12:28:06 GMThttps://www.rpharms.com/news/details//NHS-England-Clinical-Policy-puberty-suppressing-hormonesNHS England has issued a commissioning position: Puberty suppressing hormones (PSH) are not available as a routine commissioning treatment option for treatment of children and young people who have geFri, 22 Mar 2024 14:45:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Fresenius-Kabi-Limited-Sodium-Chloride-Intravenous-Infusion-FreeflexFresenius Kabi Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA)of an error on the infusion bag packaged into the specific batches of Sodium Chloride Intravenous InfuThu, 21 Mar 2024 14:38:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Besins-Healthcare-UK-Ltd-Oestrogel-Pump-Pack-750microgramsactuation-gel-estradiolBesins Healthcare (UK) Ltd has informed the MHRA that a defective pump system was detected in two batches of Oestrogel Pump-Pack 750micrograms/actuation Gel. The product pumps are subject to mechanicaTue, 19 Mar 2024 15:00:55 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-medac-GmbH-ta-medac-Pharma-LLP-Sodiofolin-50-mgml-solution-for-injectioninfusion-folinic-acid-400mg8ml-vialThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 medicines recall for a specific batch of medac GmbH (t/a medac Pharma LLP) Sodiofolin 50 mg/ml, solution for injeTue, 12 Mar 2024 15:39:26 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-Of-Salbutamol-25mg25ml-And-5mg25ml-Nebuliser-Liquid-Unit-Dose-VialsA Medicines Supply Notification (MSN) issued on 14 February 2024, detailed a shortage of salbutamol 2.5mg/2.5ml and 5mg/2.5ml nebuliser liquid. The resolution date is to be confirmed. Further informatMon, 26 Feb 2024 13:40:14 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Orifarm-UK-Ltd-Concerta-XL-18mg--36-mg-prolonged-release-tabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines defect information for Orifarm UK Ltd, Concerta XL 18mg & 36 mg prolonged release tablets. Orifarm Mon, 26 Feb 2024 12:03:30 GMThttps://www.rpharms.com/news/details//Valproate-important-new-regulatory-measures-for-oversight-of-prescribing-to-new-patients-and-existing-female-patientsThe Commission on Human Medicines recommended further restrictions to valproate use to reduce avoidable harm, these were introduced in January. These restrictions are that: Valproate must not be stWed, 21 Feb 2024 16:28:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Novartis-Pharmaceuticals-UK-Limited-Adakveo-10-mgml-concentrate-for-solution-for-infusionNovartis Pharmaceuticals UK Limited is recalling Adakveo 10 mg/ml concentrate for solution for infusion due to the benefit-risk balance of Adakveo no longer being considered favourable by the MedicineWed, 21 Feb 2024 11:25:51 GMThttps://www.rpharms.com/news/details//Drug-Safety-update-Pseudoephedrine-very-rare-risk-of-posterior-reversible-encephalopathy-syndrome-PRES-and-reversible-cerebral-vasoconstriction-syndrome-RCVSThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Drug Safety Update for pseudoephedrine. There have been very rare reports of posterior reversible encephalopathy syndrome (PTue, 20 Feb 2024 12:16:00 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Codeine-linctus-codeine-oral-solutions-reclassification-to-prescription-only-medicineThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update on the reclassification of codeine linctus to a prescription-only medicine (POM). Following a review Tue, 20 Feb 2024 12:09:24 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Torrent-Pharma-UK-Limited-Ramipril-125mg-tabletsTorrent Pharma (UK) Limited is recalling specific batches of Ramipril 1.25mg tablets as a precautionary measure due to these batches having a low assay and high related substances test results after tTue, 13 Feb 2024 11:52:12 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Exeltis-UK-Limited-Gepretix-100mg-CapsulesExeltis UK Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA) regarding an inconsistency in the Patient Information Leaflet (PIL) packaged in cartons of the specified Thu, 01 Feb 2024 16:50:26 GMThttps://www.rpharms.com/news/details//New-valproate-safety-measures-apply-from-31-January-2024The Medicines and Healthcare products Regulatory Agency (MHRA) has published a news story on the new regulatory measures for valproate which come into force from 31 January 2024. These new regulatory Wed, 31 Jan 2024 11:09:24 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Cadila-Pharmaceuticals-UK-Limited-Pantoprazole-40-mg-Gastro-Resistant-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Information for Pantoprazole 40mg Gastro-Resistant tablets. Crescent Pharma Limited has informedTue, 30 Jan 2024 12:54:42 GMThttps://www.rpharms.com/news/details//Fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriateSystemic fluoroquinolones must now only be prescribed when other commonly recommended antibiotics are inappropriate. This follows a review by the MHRA which looked at the effectiveness of current measThu, 25 Jan 2024 13:33:25 GMThttps://www.rpharms.com/news/details//Omega-3-acid-ethyl-ester-medicines-dose-dependent-increased-risk-of-atrial-fibrillation-in-patients-with-established-cardiovascular-diseases-or-cardiovascular-risk-factorsSystematic reviews and meta-analyses of randomised controlled trials have highlighted a dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or carThu, 25 Jan 2024 13:16:00 GMThttps://www.rpharms.com/news/details//Legislative-changes-to-enable-the-prescribing-supply-and-administering-of-controlled-drugs-by-certain-healthcare-professionals-The Home Office has made changes to the Misuse of Drugs Regulations 2001 to enable the prescribing, supply and administering of controlled drugs by certain healthcare professionals. Paramedic indepeWed, 24 Jan 2024 15:07:00 GMThttps://www.rpharms.com/news/details//Drug-Safety-Alert-Valproate-new-safety-and-educational-materials-to-support-regulatory-measures-in-men-and-women-under-55-years-of-ageNew safety and educational materials have been introduced for men and women and healthcare professionals to reduce the harms from valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono Tue, 23 Jan 2024 12:10:04 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-USV-UK-Limited-Sugammadex-100-mgml-solution-for-injection-2ml-vialUSV UK Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that a batch of Sugammadex 100 mg/ml solution for injection (2 ml vial) may contain some vials that contain aThu, 18 Jan 2024 13:35:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Quadrant-Pharmaceuticals-Ltd-Cozaar-100mg-film-coated-tabletsQuadrant Pharmaceuticals Ltd has informed the Medicines and Healthcare products Regulatory Agency (MHRA)of an error with the Patient Information Leaflets (PILs) in the specified batches of Cozaar 100mThu, 04 Jan 2024 10:02:03 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-of-GLP-1-receptor-agonists-update-The supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) continue to be limited, with supply not expected to return to normal until at least the end of 2024. The supply issues have been caWed, 03 Jan 2024 14:29:00 GMThttps://www.rpharms.com/news/details//Influenza-Season-202324-Use-Of-Antiviral-Medicines-in-ScotlandRecent intelligence provided by Public Health Scotland (PHS) indicates that influenza is circulating in the community.This may lead to an increase in numbers of people presenting with influenza-like iThu, 21 Dec 2023 15:36:00 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Vitamin-B12-hydroxocobalamin-cyanocobalamin-advise-patients-with-known-cobalt-allergy-to-be-vigilant-for-sensitivity-reactionsThe medicines used to treat vitamin B12 deficiency (hydroxocobalamin, cyanocobalamin) contain cobalt. There are case reports in the literature describing cobalt sensitivity-type reactions in patients Mon, 18 Dec 2023 16:17:54 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-AripiprazoleThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update for aripiprazole. Healthcare professionals prescribing aripiprazole are reminded to be alert to the riMon, 18 Dec 2023 16:16:38 GMThttps://www.rpharms.com/news/details//Influenza-Season-202324-Use-Of-Antiviral-Medicines-in-EnglandUK Health Security Agency (UKHSA) surveillance data indicates that influenza is circulating in the community. Prescribers working in primary care may now prescribe, and community pharmacists may now Fri, 15 Dec 2023 13:24:49 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Biocon-Pharma-UK-Ltd-Posaconazole-Biocon-100mg-Gastro-resistant-TabletsBiocon Pharma UK Limited are recalling a specific of batch Posaconazole 100mg Gastro-resistant Tablets due to an out of trend result for unspecified impurities during testing for stability. Further iThu, 14 Dec 2023 13:22:26 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Atnahs-Pharma-UK-Limited-Clobazam-Atnahs-5mg5ml-and-10mg5ml-Oral-SuspensionAtnahs Pharma UK Ltd has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the batches of Clobazam Atnahs 5mg/5ml and 10mg/5ml Oral Suspension listed in the alert do not conWed, 13 Dec 2023 11:37:02 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Potential-for-inappropriate-dosing-of-insulin-when-switching-insulin-degludec-Tresiba-productsA Medicine Supply Notification issued on 24 May 2023, detailed a shortage of Tresiba® (insulin degludec) FlexTouch® 100units/ml solution for injection 3ml pre-filled pens. Advice on how to manFri, 08 Dec 2023 11:22:55 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert--Potential-contamination-of-some-carbomer-containing-lubricating-eye-products-with-Burkholderia-cenocepacia--measures-to-reduce-patient-riskUKHSA is investigating an outbreak of Burkholderia cenocepacia involving individuals across the UK. This is an emerging issue and, following testing, B. cenocepacia was recovered from some lubricatingFri, 08 Dec 2023 11:19:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Strandhaven-Ltd-ta-Somex-Pharma-Clarithromycin-250mg-and-500mg-film-coated-tabletsStrandhaven Limited t/a Somex Pharma has informed the Medicines and Healthcare products Regulatory Agency (MHRA)regarding an error with the Patient Information Leaflets (PILs) that have been packed inWed, 06 Dec 2023 14:02:06 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Strandhaven-Ltd-ta-Somex-Pharma-Tramadol-Hydrochloride-50mg-Capsules-HardStrandhaven Limited t/a Somex Pharma has informed the Medicines and Healthcare products Regulatory Agency (MHRA)regarding an error with the Patient Information Leaflets (PILs) that have been packed inWed, 06 Dec 2023 11:40:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Teva-UK-Ltd-Caramet-25100mg-CR-TabletsTeva UK Ltd. has informed the Medicines and Healthcare products Regulatory Agency (MHRA) of a labelling error on a specific batch of Caramet 25/100mg CR Tablets. The Active Pharmaceutical Ingredient (Mon, 04 Dec 2023 11:59:16 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-AstraZeneca-UK-Ltd-Fluenz-Tetra-nasal-spray-suspensionAstraZeneca UK Ltd. has informed the MHRA that, following routine stability analysis, the printed expiry date for the listed batches of Fluenz Tetra nasal spray suspension is incorrect. Further inforThu, 30 Nov 2023 10:50:47 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Valproate-organisations-to-prepare-for-new-regulatory-measures-for-oversight-of-prescribing-to-new-patients-and-existing-female-patientsThe MHRA is asking organisations to put a plan in place to implement new regulatory measures for sodium valproate, valproic acid and valproate semisodium (valproate). This follows a comprehensive reviWed, 29 Nov 2023 09:30:00 GMThttps://www.rpharms.com/news/details//MHRA-Device-Safety-Information---Carbomer-Gel-Eye-ProductsSpecific batches of carbomer gel are being recalled as a precaution due to possible microbiological contamination. There is a potential risk of contamination of specific brands of carbomer eye gels wiFri, 24 Nov 2023 13:24:00 GMThttps://www.rpharms.com/news/details//ADHD-medicines-supply-disruption-update-A National Patient Safety Alert was issued in September 2023 for a number of medicines used to treat Attention Deficit Hyperactivity Disorder (ADHD). Further information has been published on the STue, 21 Nov 2023 12:06:20 GMThttps://www.rpharms.com/news/details//Preparing-for-measles-resurgence-in-EnglandThe UK Health Security Agency (UKHSA) has written to healthcare professionals working in primary care about preparing for measles resurgence in England. The UK Health Security Agency (UKHSA) recentlyFri, 03 Nov 2023 13:06:00 GMThttps://www.rpharms.com/news/details//Isotretinoin-Roaccutane-introduction-of-new-safety-measures-including-additional-oversight-of-the-initiation-of-treatment-for-patients-under-18-years-of-ageThe Medicines and Healthcare Products Regulatory Agency (MHRA) has introduced new safety measures for Isotretinoin (Roaccutane). These new safety measures strengthen the safe use of isotretinoin throuThu, 02 Nov 2023 12:20:05 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Sandoz-Limited-Zinacef-powder-for-solution-for-injection-or-infusion-vials-all-strengths-including-stock-in-GSK-liveryThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Information for Sandoz Limited, Zinacef powder for solution for injection or infusion vials (allTue, 24 Oct 2023 09:43:39 GMThttps://www.rpharms.com/news/details//Full-pack-dispensing-of-valproate-containing-medicinesLegal changes have come into force for England, Scotland and Wales to ensure that all patients (male and female) receive their valproate-containing medicine in the manufacturer’s original full pWed, 11 Oct 2023 10:05:00 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-of-verteporfin-15mg-powder-for-solution-for-injectionA National Patient Safety Alert has been issued due to a shortage of verteporfin 15mg powder for solution for injection. Verteporfin is indicated for the treatment of adults with exudative (wet) age-rFri, 29 Sep 2023 08:17:11 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Max-Remedies-Ltd-Max-Healthcare-Paracetamol-500-mg-CapsulesThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines deflection information for Max Healthcare Paracetamol 500 mg Capsules. Max Remedies has identified an iFri, 29 Sep 2023 08:16:41 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-of-methylphenidate-prolonged-release-capsules-and-tablets-lisdexamfetamine-capsules-and-guanfacine-prolonged-release-tabletsA National Patient Safety Alert has been issued due supply disruptions affecting various strengths of specified medications which are licensed for thetreatment of attention deficit hyperactivity disorWed, 27 Sep 2023 14:11:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Chiesi-Ltd-Trimbow-8759-mcg-pressurised-inhalation-solutionChiesi Ltd has informed the Medicines and Healthcare products Regulatory Agency (MHRA) about a potential issue with specific batches of Trimbow 87/5/9 mcg pressurised inhalation solution. This is due Wed, 20 Sep 2023 14:53:38 GMThttps://www.rpharms.com/news/details//Urgent-public-health-message-Food-botulism-outbreak-in-France-involving-British-nationalsThe UK Health Security Agency (UKHSA) has been notified about an outbreak of food botulism in France involving a small number of British nationals. The outbreak has been linked to consumption of home-Fri, 15 Sep 2023 08:51:30 GMThttps://www.rpharms.com/news/details//Company-led-medicines-recall-Sun-Pharma-UK-Ltd-Gemcitabine-10mgml-Solution-for-InfusionSun Pharma UK Ltd has informed the MHRA of a labelling issue with one batch of Gemcitabine 2000mg/200ml infusion. This recall is being issued as a company-led recall due to a limited number of units bThu, 07 Sep 2023 12:45:19 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Colgate-Palmolive-UK-Limited-Duraphat-5000ppm-Fluoride-ToothpasteColgate-Palmolive (U.K.) Limited has informed the MHRA that the Patient Information Leaflet (PIL), carton and tube of specified batches of Duraphat 5000ppm Fluoride Toothpaste (51g) are missing informThu, 07 Sep 2023 12:41:58 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Theramex-HQ-UK-Ltd-Evorel-SequiTheramex has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that some cartons of Evorel Sequi contain the incorrect combination of patches. An error at the packaging site meanTue, 05 Sep 2023 10:40:13 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Kyowa-Kirin-Limited-Tostran-Testosterone-2-percent-gelThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect information for Tostran (Testosterone, 2% gel). Kyowa Kirin Limited has notified MHRA that the pThu, 31 Aug 2023 12:47:00 GMThttps://www.rpharms.com/news/details//Drug-Safety-Updates-Fluoroquinolones-Methotrexate-ValproateThe Medicines and Healthcare products Regulatory Agency (MHRA) has published three new Drug Safety Updates: Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lastingThu, 31 Aug 2023 10:07:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Veriton-Pharma-Limited-Epistatus-25-mg-oromucosal-solution-pre-filled-syringe-PFSThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 recall for a specified batch of Epistatus 2.5mg oromucosal solution, pre-filled syringe (PFS). The recall is due Wed, 30 Aug 2023 14:42:51 GMThttps://www.rpharms.com/news/details//Update-on-the-COVID-19-vaccination-programme-for-autumn-2023The Department of Health and Social Care (DHSC) has issued a press release about bringing forward Flu and COVID autumn vaccine programmes as a precautionary measure taken to protect those most vulneraWed, 30 Aug 2023 13:35:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Galderma-UK-Limited-Loceryl-5-percent-wv-Medicated-Nail-LacquerThe Medicines and Healthcare products Regulatory Agency (MHRA) has published Class 4 Medicines Defect information for Loceryl 5%w/v Medicated Nail Lacquer. Galderma (U.K.) Limited has informed the MHRTue, 29 Aug 2023 09:48:00 GMThttps://www.rpharms.com/news/details//Serious-Shortage-Protocol-SSP-for-Jext-300micrograms03ml-1-in-1000-solution-for-injection-auto-injector-penThe Department of Health and Social Care (DHSC) hasissued Serious Shortage Protocol (SSP) for Jext® 300micrograms/0.3ml (1 in 1000) solution for injection auto-injector pen: Jext® 300micrograThu, 24 Aug 2023 14:16:21 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Accord-Healthcare-Limited-UK-Irinotecan-Hydrochloride-20-mgml-Concentrate-for-Solution-for-InfusionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Notification for Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion.Accord HealthcWed, 23 Aug 2023 13:04:52 GMThttps://www.rpharms.com/news/details//MHRA-Device-Safety-Information-Ethypharm-Aurum-pre-filled-syringes-are-incompatible-with-some-manufactured-needle-free-connectors-risk-of-delay-in-administering-potentially-lifesaving-medicationThe Medicines and Healthcare products Regulatory Agency (MHRA) has published Device Safety Information for Ethypharm Aurum pre-filled syringes. Attaching an incompatible needle-free connector (NFC) toTue, 22 Aug 2023 13:49:59 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Notification-Accord-Healthcare-Limited-UK-Olmesartan-Medoxomil-film-coated-tabletsAccord Healthcare Ltd, UK has informed the Medicines and Healthcare products Regulatory Agency (MHRA) about an error with the Patient Information Leaflets (PILs) that have been packaged in the specifiTue, 22 Aug 2023 13:40:03 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-medac-GmbH-ta-medac-Pharma-LLP-Sodiofolin-50-mgml-solution-for-injectioninfusionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 recall for further batches of medac GmbH (t/a medac Pharma LLP) Sodiofolin 50 mg/ml solution for injection/infusiMon, 21 Aug 2023 15:33:03 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-B-Braun-Medical-Ltd-Various-ProductsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 medicines recall. B. Braun Medical Limited is recalling the specific product batches as a precautionary measure aMon, 31 Jul 2023 13:57:52 GMThttps://www.rpharms.com/news/details//Nation-Patient-Safety-Alert-Potent-synthetic-opioids-implicated-in-heroin-overdoses-and-deathsThe Office for Health Improvements and Disparities has issued a National Patient Safety Alert on potent synthetic opioids implicated in heroin overdoses and deaths. In the past 8 weeks there has beeWed, 26 Jul 2023 11:55:56 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Hyoscine-hydrobromide-patches-Scopoderm-15mg-Patch-or-Scopoderm-TTS-Patch-risk-of-anticholinergic-side-effects-including-hyperthermiaThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update for hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch). There have been a smTue, 25 Jul 2023 09:21:23 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-medac-GmbH-ta-medac-Pharma-LLP-Sodiofolin-50-mgml-solution-for-injectioninfusion-400mg8ml-vialThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 recall for specified batches of Sodiofolin 50 mg/ml, solution for injection/infusion (400mg/8ml vial),due to particlThu, 20 Jul 2023 13:14:59 GMThttps://www.rpharms.com/news/details//Company-led-medicines-recall-Quantum-PharmaceuticalThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Company led medicines recall for specified batches of Diltiazem HCI 2% Cream [unlicensed medicine]. This is because the consWed, 19 Jul 2023 12:34:18 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-of-GLP-1-receptor-agonistsA National Patient Safety Alert has been issued due to the shortage of GLP-1 receptor agonists. There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RATue, 18 Jul 2023 11:56:18 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Aventis-Pharma-Limited-ta-Sanofi-Sabril-500-mg-film-coated-tablets--Sabril-500-mg-granules-for-oral-solutionThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 recall for specified batches of Sabril tablets and Sabril granules as a precautionary measure due to the detection oThu, 13 Jul 2023 14:55:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Tillomed-Laboratories-Limited-Labetalol-200mg-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 recall for a specific batchof Tillomed Laboratories Limited, Labetalol 200mg Tablets. The batch is being recalled duMon, 10 Jul 2023 14:05:08 GMThttps://www.rpharms.com/news/details//Medicines-Supply-Notification-GLP-1-receptor-agonists-used-in-the-management-if-type-2-diabetesThe Department of Health and Social Care (DHSC) has issued a Medicine Supply Notification for GLP-1 receptor agonists. There are very limited, intermittent supplies of all glucagon-like peptide-1 receWed, 05 Jul 2023 13:00:38 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-medac-GmbH-ta-medac-Pharma-LLP-Dacarbazine-100mg-200mg--500mg-powder-for-solution-for-injection-vialsThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 recall for specific batches of medac GmbH (t/a medac Pharma LLP), dacarbazine 100mg, 200mg and 500mg powder for soluTue, 04 Jul 2023 14:40:00 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Strandhaven-Limited-TA-Somex-Pharma-Sildenafil-100mg-Film-coated-TabletsThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 recall for a specific batch of Sildenafil 100mg tablets. Strandhaven Limited T/A Somex Pharma has informed the MHTue, 04 Jul 2023 09:34:47 GMThttps://www.rpharms.com/news/details//Non-steroidal-anti-inflammatory-drugs-NSAIDs-potential-risks-following-prolonged-use-after-20-weeks-of-pregnancyThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update on the potential risks of non-steroidal anti-inflammatory drugs (NSAIDs) following prolonged use afterWed, 28 Jun 2023 10:49:29 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Potential-risk-of-underdosing-with-calcium-gluconate-in-severe-hyperkalaemiaA National Patient Safety Alert has been issued on the Potential risk of underdosing with calcium gluconate in severe hyperkalaemia. This alert highlights theAdult Renal Association Clinical Practice Tue, 27 Jun 2023 14:55:41 GMThttps://www.rpharms.com/news/details//New-guidance-on-the-use-of-lifesaving-adrenaline-auto-injectors-AAIsThe Medicines and Healthcare products Regulatory Agency (MHRA) has shared new guidance to highlight the latest safety advice on the steps to take during anaphylaxis. This new guidance includes an easyWed, 21 Jun 2023 08:10:44 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Tricodent-Limited-supplier-Medical-Oxygen-BP-MEDIGAS-OXYGEN-BPThe Medicines and Healthcare products Regulatory Agency (MHRA) has been made aware that falsified medical oxygen has been provided to several dental practices across the UK. The source of the supply hTue, 06 Jun 2023 10:51:37 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Shortage-of-Pyridostigmine-60mg-tabletsThe Department of Health and Social Care has issued a National Patient Safety Alert due to a shortage of Pyridostigmine 60mg tablets. Pyridostigmine 60mg tablets are out of stock, resupply is expecteWed, 24 May 2023 15:48:27 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Orifarm-UK-Ltd-Buccolam-10mg-Oromucosal-solutionThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 Medicines Defect Information for Orifarm UK Ltd, Buccolam 10mg Oromucosal solution. Orifarm UK Ltd has informed the Mon, 22 May 2023 15:13:33 GMThttps://www.rpharms.com/news/details//-Class-4-Medicines-Defect-Information-Novartis-Pharmaceuticals-Simulect-10mg--20mg-powder-and-solvent-for-Solution-for-injection-or-infusionThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 recall for Novartis Pharmaceuticals, Simulect 10mg & 20mg powder and solvent for Solution for injection or infusThu, 18 May 2023 12:44:24 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Hikma-Farmacutica-Portugal-SA-Gemcitabine-1g263ml--2g526ml-Solution-For-Infusion-VialThe Medicines and Healthcare products Regulatory Agency (MHRA) has been informed of a potential issue impacting specific batches of Gemcitabine 1g/26.3ml & 2g/52.6ml Solution For Infusion Vial. DuWed, 10 May 2023 14:30:00 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Class-1-Medicines-Recall-Notification-Recall-of-Emerade-500-micrograms-and-Emerade-300-micrograms-auto-injectors-due-to-the-potential-for-device-failureThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a National Patient Safety Alert for Emerade 500 micrograms and Emerade 300 micrograms. Pharmaswiss Česka republika s.r.o.Tue, 09 May 2023 13:00:21 GMThttps://www.rpharms.com/news/details//NHS-England-Influenza-season-202223-ending-the-prescribing-and-supply-of-antiviral-medicines-in-primary-careThe most recent surveillance data from UK Health Security Agency (UKHSA) indicates that circulation of influenza in the community has returned to baseline levels. In accordance with NICE guidance aTue, 09 May 2023 12:58:37 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Omega-Pharma-Ltd-Beconase-Hayfever-Nasal-SprayOmega Pharma Ltd has identified that there is text missing in Section 2 of the Patient Information Leaflet (PIL) in packs of Beconase Hayfever Nasal Spray (P). Further information, details of the aWed, 26 Apr 2023 14:44:07 GMThttps://www.rpharms.com/news/details//Drug-Safety-Update-Isotretinoin-Roaccutane-new-safety-measures-to-be-introduced-in-the-coming-months-including-additional-oversight-on-initiation-of-treatment-for-patients-under-18-yearsThe Isotretinoin Expert Working Group of the Commission on Human Medicines has made recommendations to strengthen the safety of isotretinoin treatment. Recommendations include new warnings, the need fWed, 26 Apr 2023 14:34:34 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Sandoz-Limited-Co-amoxiclav-1253125mg5ml-250625mg5ml-powder-for-oral-suspensionSandoz limited has informed theMedicines and Healthcare products Regulatory Agency (MHRA) that Co-amoxiclav 125/31.25mg/5ml, 250/62.5mg/5ml powder for oral suspension are not sugar free despite the caThu, 20 Apr 2023 12:59:48 GMThttps://www.rpharms.com/news/details//Company-led-medicines-recall-Spectrum-Therapeutics-UK-Canopy-AKH-22-Dried-Cannabis-5g-unlicensed-medicineThe importer and distributor of the above products has informed the Medicines and Healthcare products Regulatory Agency (MHRA) of reports that the microbial limit for Total Microbial Aerobic Count (TAThu, 20 Apr 2023 09:59:21 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Ethigen-Limited-Briviact-75mg--100mg-film-coated-tabletsEthigen Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the Patient Information Leaflet (PIL) in Briviact 75mg and Briviact 100mg film coated tablets contains Thu, 30 Mar 2023 14:01:21 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Ferring-Pharmaceuticals-Limited-GONAPEPTYL-Depot-375mg-Powder-and-solvent-for-suspension-for-injectionFerring Pharmaceuticals Limited is recalling certain batches of GONAPEPTYL Depot 3.75mg due to a defect noticed in the seal of the needle wrapping for the CE-marked 30-millimeter (30mm) needle for subThu, 23 Mar 2023 12:11:57 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Rosemont-Pharmaceuticals-Limited-Sildenafil-10mgml-Oral-SuspensionThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 3 recall for a specific batch of Rosemont Pharmaceuticals Limited, Sildenafil 10mg/ml Oral Suspension. Rosemont PhaTue, 21 Mar 2023 15:05:50 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Macarthys-Laboratories-ta-Martindale-Pharma-Venlafaxine-XL-150mg-225mg-300mg-prolonged-release-tabletsAdditional to the batches included in the previous Class 4 Medicines Notification from 16th November 2022. Martindale Pharma has made the MHRA aware that the GTIN in the 2D barcode and the printed varThu, 16 Mar 2023 13:05:29 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-and-Drug-Safety-Update-All-pholcodine-containing-medicinesThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 drug recall for all pholcodine-containing medicines. All pholcodine-containing medicines are being recalled and withTue, 14 Mar 2023 11:20:04 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Drugsrus-Limited-Clexane-10000-IU-100mg--1ml-SyringesDrugsrus Limited has informed the MHRA that the Patient Information Leaflet (PIL) packaged in specific batches of Clexane 10,000IU (100mg)/1 ml Syringes contains a typographical error in the leaflet. Thu, 09 Mar 2023 11:20:39 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Thornton--Ross-Ltd-Methadone-1mgmL-Oral-Solution-BP---Sugar-Free-Methadone-Mixture-1mgml-Thornton & Ross Ltd has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that specific batches of Methadone 1mg/mL Oral Solution BP Sugar Free have been packaged with the inTue, 07 Mar 2023 14:43:51 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Teva-UK-Limited-Levothyroxine-125mcg-TabletsTeva UK Limited is recalling one batch of Levothyroxine 12.5mcg Tablets in response to a lower than required assay result discovered during routine stability testing. Further information, advice and Thu, 02 Mar 2023 11:59:19 GMThttps://www.rpharms.com/news/details//Extension-to-Serious-Shortage-Protocols-for-phenoxymethylpenicillinThe eight Serious Shortage Protocols (SSPs) for phenoxymethylpenicillin products have been extended. They have been extended for a further month and are now due to expire on Friday 31 March 2023. STue, 28 Feb 2023 16:43:09 GMThttps://www.rpharms.com/news/details//Company-led-medicines-recall-Vertical-Pharma-Resources-Ltd-TA-IPS-Pharma-Levothyroxine-Oral-Suspension-Various-Strengths-unlicensed-medicineIPS Pharma is recalling specific batches of levothyroxine oral suspension from pharmacies and impacted patients due to the concentration of levothyroxine being greater than the amount stated on the laMon, 27 Feb 2023 17:14:59 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Atnahs-Pharma-UK-Zestoretic-20mg125mg-TabletsAtnahs Pharma UK has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the Patient Information Leaflet (PIL) packaged in specific batches of Zestoretic 20mg/12.5mg tablets cMon, 27 Feb 2023 13:28:29 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Reckitt-Benckiser-Healthcare-UK-Limited-Lemsip-Max-Cold-and-Flu-CapsulesReckitt Benckiser Healthcare (UK) Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that a typographical error has been identified on the end flap of the outer cartonThu, 23 Feb 2023 10:00:01 GMThttps://www.rpharms.com/news/details//MHRA-Device-Safety-Information-BD-BodyGuard-MicroSets-and-residual-ethylene-oxideThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued a device safety information for BD BodyGuard MicroSets and residual ethylene oxide. Devices may continue to be used to treat pTue, 21 Feb 2023 14:07:30 GMThttps://www.rpharms.com/news/details//Group-A-Streptococcus-reinstatement-of-NICE-sore-throat-guidance-for-children-and-young-people-and-withdrawal-of-NHS-England-interim-guidanceThe NHS England/UKHSA Incident Management Team Group A Streptococcus interim clinical guidance for primary and community care settings has been retired as of 15 February 2023. This guidance asked heaThu, 16 Feb 2023 13:12:27 GMThttps://www.rpharms.com/news/details//Changes-and-extension-to-Serious-Shortage-Protocols-for--phenoxymethylpenicillin-products-The eight Serious Shortage Protocols (SSPs) for phenoxymethylpenicillin products have been extended. The revised date is now 28 February 2023. Phenoxymethylpenicillin 125mg/5ml oral solution sugar Wed, 01 Feb 2023 10:56:00 GMThttps://www.rpharms.com/news/details//Company-led-medicines-recall-Prulab-Pharma-Limited-Clopidogrel-Oral-Solution-75mg-in-5ml-unlicensed-medicinePrulab Pharma Limited is recalling a batch of Cloipidogrel Oral Solution 75mg in 5ml due to a discrepancy with the product labelling that could result in an incorrect volume to be administered to the Thu, 26 Jan 2023 11:09:47 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Supply-of-Licensed-and-Unlicensed-Epidural-Infusion-BagsThe Department of Health and Social Care (DHSC) has issued a National Patient Safety Alert for the supply of licensed and unlicensed epidural infusion bags. There are supply issues impacting FreseniusMon, 23 Jan 2023 17:07:34 GMThttps://www.rpharms.com/news/details//Class-3-Medicines-Recall-Dr-Reddys-Laboratories-UK-Ltd-Lacidipine-4-mg-Film-Coated-TabletsDr Reddy’s Laboratories (UK) Limited is recalling two batches of Lacidipine 4 mg Film-Coated Tablets as a precautionary measure due to the presence of an unknown solvent-like odour. Further infThu, 19 Jan 2023 14:48:27 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-UCB-Pharma-Ltd-Dioctyl-100-mg-CapsulesUCB Pharma Ltd is recalling one batch of Dioctyl 100 mg Capsules as a precautionary measure due to the presence of a foreign capsule being found in a sealed pack. The Marketing Authorisation Holder&rsWed, 18 Jan 2023 15:26:49 GMThttps://www.rpharms.com/news/details//Company-led-medicines-recall-Mawdsley-Brooks--Company-Limited-Fluphenazin-neuraxpharm-D-25--100-mgml-Solution-for-InjectionMawdsley-Brooks & Company Limited is recalling specific batches of Fluphenazin-neuraxpharm® D 25 & 100 mg/ml Solution for injection as a precautionary measure, due to validation tests demoThu, 12 Jan 2023 15:12:20 GMThttps://www.rpharms.com/news/details//National-Patient-Safety-Alert-Use-of-oxygen-cylinders-where-patients-do-not-have-access-to-medical-gas-pipeline-systemsNHS England has published a National Patient Safety Alert on the use of oxygen cylinders where patients do not have access to medical gas pipeline systems. To help NHS organisations prevent risks assoTue, 10 Jan 2023 15:58:32 GMThttps://www.rpharms.com/news/details//Updated-illustration-summarising-the-substitution-options-provided-by-the-SSPs-for-phenoxymethylpenicillin-products-We have updated ourillustration(Version 7)that summarises thesubstitution options provided by the SSPs for phenoxymethylpenicillin products. This follows a number of enquiries that our professional suWed, 04 Jan 2023 14:52:00 GMThttps://www.rpharms.com/news/details//Class-4-Medicines-Defect-Information-Albireo-AB-Bylvay-1200-micrograms-Hard-CapsulesAlbireo AB has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that there is a typographical error with the text on the side panel of the bottle label for a specific batch of BTue, 03 Jan 2023 15:03:50 GMThttps://www.rpharms.com/news/details//UKHSA--Urgent-Public-Health-Message-Enhanced-genome-sequencing-for-hospitalised-patients-returning-from-ChinaThe UK Health Security Agency (UKHSA) has published an urgent public health message for enhanced genome sequencing for hospitalised patients returning from China. China is currently experiencing its Tue, 03 Jan 2023 11:59:22 GMThttps://www.rpharms.com/news/details//Updated-illustration-summarising-the-substitution-options-provided-by-the-SSPs-for-phenoxymethylpenicillin-productsWe have updated our illustration that summarises thesubstitution options provided by the SSPs for phenoxymethylpenicillin products. This is following two amendements that were made on 23 December 2022Wed, 28 Dec 2022 16:42:00 GMThttps://www.rpharms.com/news/details//Class-2-Medicines-Recall-Crescent-Pharma-Limited-Ramipril-5mg-capsulesThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 2 medicines recall for ramipril 5mg capsules. Crescent Pharma Limited is recalling one batch of Ramipril 5 mg CapsuThu, 01 Jan 1970 00:00:00 GMT